Evaluation of the safety of Feline Herpes Virus, bivalent deleted live vaccine, administered as intranasal vaccine to cats

×

Message d'erreur

  • Notice : Trying to access array offset on value of type null dans bootstrap_pager() (ligne 53 dans /var/www/biosafety.be/sites/all/themes/bootstrap/templates/system/pager.func.php).
  • Notice : Trying to access array offset on value of type null dans bootstrap_pager() (ligne 95 dans /var/www/biosafety.be/sites/all/themes/bootstrap/templates/system/pager.func.php).
Study title: 
Evaluation of the safety of Feline Herpes Virus, bivalent deleted live vaccine, administered as intranasal vaccine to cats
EU record number: 
B/BE/04/BV1
Company / Sponsor: 
Pfizer, Animal Health Group
Treated organism: 
cats
Indication category: 
prevention and/or reduction of infection caused by Feline immunodeficiency virus (FIV)
Genetic modification: 
gene for the env glycoprotein or gene for the gag protein of the Feline immunodeficiency virus (FIV)
Method of transfer of nucleic acid of interest: 
Feline Herpes Virus
Route of administration: 
intranasal
Locations in Belgium: 
Mechelen, Sint Katelijne-Waver and Schaerbeek
Nr of subjects: 
at least 40 animals, maximum 1000 animals
Foreseen duration: 
1 year
Type of procedure: 
Deliberate release only

Information related to the decision procedure